Latest CD44 Stories
FORT LAUDERDALE, Fla., April 21, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and
Phase I studies start in 2015 NEW HAVEN, Conn., July 25, 2014 /PRNewswire/ -- Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd.
Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 BOSTON, June 17, 2014 /PRNewswire/ -- Australian oncology drug development company Novogen
The retinoblastoma (Rb) protein plays a critical role in suppressing the multi-step process of cell migration through the bloodstream, lymphovascular invasion and the metastasis of an aggressive type of breast cancer to the lung.
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.
Breast cancer stem cells wear a cell surface protein that is part nametag and part bull's eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug.
Idiopathic pulmonary fibrosis (IPF) affects about 100,000 people in the US each year and is fatal within three years of diagnosis.
Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.
A newly discovered hybrid gene appears to play a direct role in some stomach cancers.
A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells.